Infectious disease
What has been learned about SARS-CoV-2, the virus that causes COVID-19, in only about 15 months, is truly a historical scientific achievement. And new information continues to come in.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
AstraZeneca released primary analysis that the vaccine demonstrated 76% efficacy against symptomatic COVID-19, 100% efficacy against severe or critical disease and hospitalizations and 85% efficacy against symptomatic COVID-19 in people 65 years and older.
Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March.
With the rise of mutant strains of SARS-CoV-2 and the unlikelihood of 100% compliance in getting vaccines out, investigators are focusing on developing even better vaccines and new drugs that might be able to knock back the disease. Here’s a look.
With widespread distribution of various vaccines against COVID-19 vaccine ongoing, companies are still refining their vaccines and therapies and generating new data. Here’s a look at two recent updates.
The announcement by the NIAID, a part of the National Institutes of Health (NIH), is very unusual.
Jerusalem’s clinical-stage pharmaceutical company Oramed Pharmaceuticals is forming a joint venture with Premas Biotech to develop novel oral COVID-19 vaccine candidates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
Per BioSpace’s 2020 U.S. Life Sciences Salary Report and 2020 U.S. Life Sciences Diversity & Inclusion Report, men out-earn women by 19.3%, which climbs to 47.6% when looking specifically at health care. Also, only 14% of women felt that opportunities for promotion were fair compared to 23% of their male counterparts.
PRESS RELEASES